Curaleaf International (formerly EMMAC Life Sciences Group) (“Curaleaf International”), Europe’s largest vertically integrated cannabis company, is pleased to announce it has successfully exported over one metric ton of medical cannabis to BOL Pharma in Israel. Curaleaf International is one of the first companies to export medical cannabis to Israel under the country’s new regulatory regime.
The initial shipment, comprising two strains of dried flower, was shipped from Curaleaf International’s primary cultivation facility, Terra Verde in Portugal, and is part of a larger supply agreement with BOL Pharma.
Kfir Avraham, CEO of BOL Pharma, added: “We are pleased to be working with Curaleaf International to bring new medical cannabis products to market. We are witnessing a significant rise in patient demand for high-quality medical cannabis products in Israel and Curaleaf International is a trusted partner to deliver consistent and reliable product to meet our market requirements.”
Commenting on the shipment, Antonio Costanzo, CEO of Curaleaf International, said: “We are delighted to have created such a strong partnership with BOL Pharma, and the completion of today’s shipment of one metric ton of medical cannabis. This partnership and the fact that we are one of the first companies exporting to Israel under the new Israeli regulatory regime reflects the high-quality standards met by Curaleaf International’s facilities and the depth of regulatory expertise in our business. We look forward to strengthening our relationship with BOL as we continue to service the growing patient demand for high quality medical cannabis in Israel.”
